Palisade Bio (PALI) Virtual Investor Closing Bell Series summary

Corporate overview and strategy

• Focus on advancing early-stage drugs for immunology and inflammatory diseases, especially those with a fibrotic component.

• Lead program is a PDE4 inhibitor (PALI-2108) targeting ulcerative colitis and Crohn's disease, with preclinical studies nearly complete and phase I human trials starting soon.

• Strategy is to advance drugs through early clinical phases and then partner with or sell to larger pharma companies for commercialization.

• The company is trading below cash value and recently raised $4 million, extending cash runway through late Q1 2025.

• Leadership and advisory board include experienced professionals and renowned IBD experts.

Scientific and clinical highlights

• PALI-2108 is a locally-activated oral prodrug designed to minimize systemic side effects and improve efficacy in ulcerative colitis.

• Addresses significant unmet need: current remission rates are low, and many patients fail first-line therapies.

• Precision medicine approach uses biomarkers to select patients most likely to respond, supported by analysis of 1,700 patient samples.

• Preclinical data show improved disease activity, colon length, and reduced TNF alpha with local delivery.

• Phase I trial to start within weeks, with top-line data expected in the first half of 2025; phase Ib/IIa studies to follow.

Market opportunity and competitive landscape

• Ulcerative colitis market exceeds $7 billion, projected to reach $10 billion in 4–5 years; company aims to address 70–80% of moderate to severe cases.

• Big Pharma has made high-value acquisitions in this space, including for preclinical assets.

• PALI-2108 is differentiated as the only PDE4 inhibitor in development for UC, with a unique local delivery mechanism.

• Additional indications include fibrostenotic Crohn’s disease and potentially other fibro-inflammatory diseases like IPF.